ClinicalTrials.Veeva
Menu

Find clinical trials for Kidney Disease in Chicago, IL

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Kidney Diseases
Chronic Renal Insufficiency
Chronic Kidney Failure
IGA Glomerulonephritis
Renal Cell Carcinoma
Renal Insufficiency
Carcinoma

Kidney Disease trials near Chicago, IL, USA:

A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

is to evaluate the effect of tolvaptan on the need for renal replacement therapy in pediatric subjects with autosomal recessive polycystic kidney...

Enrolling
Autosomal Recessive Polycystic Kidney Disease (ARPKD)
Drug: Tolvaptan (OPC-41061)

Phase 3

Otsuka
Otsuka

Chicago, Illinois, United States and 17 other locations

Powerful new drugs that can prevent or delay end stage kidney disease (ESKD) - so called sodium-glucose cotransporter-2 inhibitors ...

Not yet enrolling
Kidney Failure, Chronic
Diabetic Nephropathies
Drug: Placebo
Drug: Sotagliflozin

Phase 3

Alessandro Doria

Chicago, Illinois, United States and 18 other locations

A) or REGN5458 (Part B) as monotherapy in patients with chronic kidney disease (CKD) who need kidney transplantation and a...

Enrolling
Chronic Kidney Disease (CKD)
Drug: REGN5458
Drug: REGN5459

Phase 1, Phase 2

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Chicago, Illinois, United States and 8 other locations

To assess the impact of RGLS8429 on height-adjusted total kidney volume (htTKV)* To characterize the pharmacokinetic (PK) properties of RGLS...

Enrolling
Polycystic Kidney, Autosomal Dominant
Autosomal Dominant Polycystic Kidney Disease
Drug: Placebo
Drug: RGLS8429

Phase 1

Regulus Therapeutics

Chicago, Illinois, United States and 27 other locations

to evaluate efficacy, safety and tolerability of treatment with zibotentan/dapagliflozin and dapagliflozin alone in participants with chronic kidney...

Enrolling
Chronic Kidney Disease With High Proteinuria
Drug: Dapagliflozin
Drug: Zibotentan/Dapagliflozin

Phase 3

AstraZeneca
AstraZeneca

Chicago, Illinois, United States and 338 other locations

Locations recently updated

of up to 2 REACT injections given 3 months (+30 days) apart and delivered percutaneously into biopsied and non-biopsied contralateral kidneys...

Enrolling
Chronic Kidney Diseases
Type 2 Diabetes Mellitus
Biological: Renal Autologous Cell Therapy (REACT)
Procedure: Sham Comparator

Phase 3

Prokidney

Chicago, Illinois, United States and 46 other locations

Primary Objective:Evaluate the effect of Hectorol® capsules in reducing elevated levels of intact parathyroid hormone (iPTH).Secondary Objectives:* E...

Active, not recruiting
Secondary Hyperparathyroidism-Chronic Kidney Disease
Drug: Doxercalciferol (GZ427397)
Drug: Calcitriol

Phase 3

Sanofi
Sanofi

Chicago, Illinois, United States and 29 other locations

The primary objective of this study is to evaluate the safety of tolvaptan in pediatric subjects with autosomal recessive polycystic kidney ...

Enrolling
Autosomal Recessive Polycystic Kidney (ARPKD)
Drug: Tolvaptan Suspension
Drug: Tolvaptan Tablets

Phase 3

Otsuka
Otsuka

Chicago, Illinois, United States and 27 other locations

CRP-lowering effect of quarterly and monthly subcutaneous administration of TOUR006 (also known as pacibekitug) in participants with chronic kidney...

Enrolling
Kidney Insufficiency, Chronic
Chronic Kidney Diseases
Drug: TOUR006 - 25 MG
Drug: TOUR006 - 50 MG

Phase 2

Tourmaline Bio

Chicago, Illinois, United States and 41 other locations

Researchers are looking for a better way to treat people who have non-diabetic chronic kidney disease (non-diabetic CKD). The trial ...

Active, not recruiting
Non-diabetic Chronic Kidney Disease
Drug: Finerenone (BAY94-8862)
Drug: Placebo

Phase 3

Bayer
Bayer

Chicago, Illinois, United States and 337 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems